Vericel (VCEL) Notes Payables (2013 - 2018)
Vericel (VCEL) posted Notes Payables of $1.5 million for Q2 2018, down 19.36% sequentially from $1.9 million in Q1 2018, and up 641.15% YoY from $209000.0 in Q2 2017.
Analysis
Vericel (VCEL) Notes Payables (2013 - 2018) Analysis & Trends
Vericel has reported Notes Payables for 6 years, with the latest figure at $1.5 million in Q2 2018.
- Quarterly Notes Payables rose 641.15% year-over-year to $1.5 million in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $1.5 million (up 641.15% YoY) and the FY2017 annual result came in at $1.0 million, up 33.95% from the prior year.
- Notes Payables declined to $1.5 million in Q2 2018 per VCEL's latest filing, from $1.9 million in the prior quarter.
- Over five years, Notes Payables peaked at $2.5 million in Q2 2014 and troughed at $209000.0 in Q2 2017.
- A 5-year average of $1.1 million and a median of $885500.0 in 2015 frame the typical range for Notes Payables.
- The sharpest annual moves came in 2016 and 2018: Notes Payables changed 0.0% in 2016, then jumped 641.15% in 2018.
- Over 5 years, Notes Payables stood at $2.5 million in 2014, then sank by 69.72% to $757000.0 in 2015, then changed by 0.0% to $757000.0 in 2016, then jumped by 33.95% to $1.0 million in 2017, then soared by 52.76% to $1.5 million in 2018.
- According to Business Quant data, Notes Payables over the past three periods registered $1.5 million, $1.9 million, and $1.0 million for Q2 2018, Q1 2018, and Q4 2017 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2018 | 1.55 Mn |
| Mar 31, 2018 | 1.92 Mn |
| Dec 31, 2017 | 1.01 Mn |
| Sep 30, 2017 | 1.27 Mn |
| Jun 30, 2017 | 209,000.00 |
| Mar 31, 2017 | 650,000.00 |
| Dec 31, 2016 | 757,000.00 |
| Sep 30, 2016 | 658,000.00 |
| Dec 31, 2015 | 757,000.00 |
| Jun 30, 2014 | 2.50 Mn |
| Dec 31, 2013 | 6,000.00 |